Tumor Biology

, Volume 35, Issue 12, pp 12467–12472 | Cite as

Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma

  • Wanli Ma
  • Xuhua Zhang
  • Jie Chai
  • Peng Chen
  • Peng Ren
  • Mingzhi Gong
Research Article


The purpose of the present study was to detect the expression levels of circulating miR-148a in the peripheral blood of osteosarcoma patients and to further investigate the clinicopathological, diagnostic, and prognostic value of miR-148a. Eighty-nine patients with initially diagnosed osteosarcoma who successfully underwent surgical resection were enrolled in this prospective study. The expression levels of circulating miR-148a were detected by real-time quantitative RT-PCR. All statistical analyses were performed with SPSS 18.0 statistical software to determine the potential values of circulating miR-148a on the clinicopathological factors, diagnosis, and prognosis. The expression levels of circulating miR-148a in osteosarcoma patients were significantly higher than that in the healthy controls (P < 0.001), and miR-148a was capable of distinguishing osteosarcoma patients from healthy controls effectively (AUC = 0.783). In addition, miR-148a expression was significantly associated with tumor size (P = 0.049) and distant metastasis (P = 0.004). Univariate survival analysis demonstrated that patients with miR-148a high expression had significantly poor overall survival (P < 0.001) and disease-specific survival (P < 0.001) after 5 years’ operation. Multivariate survival analysis confirmed that miR-148a high expression was an independent predictor for unfavorable overall survival (P = 0.003) and disease-specific survival (P = 0.008), respectively. Our findings demonstrated that detection of circulating miR-148a expression in the peripheral blood have clinical potentials as an indicator of progressive phenotype, a novel diagnostic biomarker and a promising predictor to identify individuals with poor prognosis for osteosarcoma patients.


Circulating miR-148a Diagnostic Prognostic biomarker Osteosarcoma 



This work was supported by the grant from the Scientific Research Project of the Second Hospital of Shandong University (Y2013010054).

The authors were grateful toYuan Zhang (Department of Evidence-based medicine) for his technical guide and data analysis from the Second Hospital of Shandong University, Shandong University, China.

Conflicts of interest



  1. 1.
    Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229–34.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Mangat KS, Jeys LM, Carter SR. Latest developments in limb-salvage surgery in osteosarcoma. Expert Rev Anticancer Ther. 2011;11:205–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Tan P, Zou C, Yong B, et al. Expression and prognostic relevance of PRAME in primary osteosarcoma. Biochem Biophys Res Commun. 2012;419:801–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Yao Y, Dong Y, Lin F, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep. 2009;21:229–35.PubMedGoogle Scholar
  5. 5.
    Jaffe N. Adjuvant chemotherapy in osteosarcoma: an odyssey of rejection and vindication. Cancer Treat Res. 2009;152:219–37.PubMedCrossRefGoogle Scholar
  6. 6.
    Baumhoer D, Smida J, Zillmer S, et al. Strong expression of CXCL12 is associated with a favorable outcome in osteosarcoma. Mod Pathol. 2012;25:522–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Dykxhoorn DM. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res. 2010;70:6401–6.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J. 2007;7:297–304.PubMedCrossRefGoogle Scholar
  11. 11.
    Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature. 2005;435:745–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Ardekani AM, Naeini MM. The role of microRNAs in human diseases. Avicenna J Med Biotech. 2010;2:161–79.Google Scholar
  13. 13.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38:724–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Chen PS, Su JL, Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci. 2012;19:90.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Croce C. Introduction to the role of microRNAs in cancer diagnosis, prognosis, and treatment. Cancer J. 2012;18:213–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Corsini LR, Bronte G, Terrasi M, et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets. 2012;16:S103–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14:1170–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, et al. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 2011;15:429–38.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng H, et al. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 2011;18:1702–10.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Takahashi M, Cuatrecasas M, Balaguer F, et al. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS ONE. 2012;7:e46684.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Fujita Y, Kojima K, Ohhashi R, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010;285:19076–84.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Murata T, Takayama K, Katayama S, et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis. 2010;13:356–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Baumhoer D, Elsner M, Smida J, et al. CRIP1 expression is correlated with a favorable outcome and less metastasis in osteosarcoma patients. Oncotarget. 2011;2:970–5.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE. 2010;5:e13735.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn. 2011;11:259–75.PubMedGoogle Scholar
  28. 28.
    Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011;12:1117–25.PubMedGoogle Scholar
  29. 29.
    Wu X, Somlo G, Yu Y, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012;10:42.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Madhavan D, Zucknick M, Wallwiener M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res. 2012;18:5972–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223–33.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–18.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Wanli Ma
    • 1
  • Xuhua Zhang
    • 2
  • Jie Chai
    • 3
  • Peng Chen
    • 1
  • Peng Ren
    • 1
  • Mingzhi Gong
    • 1
  1. 1.Department of Orthopedics, the Second Hospital of Shandong UniversityShandong UniversityJinanChina
  2. 2.Department of Clinical Laboratory, the Second Hospital of Shandong UniversityShandong UniversityJinanChina
  3. 3.Department of Gastrointestinal SurgeryCancer Prevention and Research Institute of Shandong ProvinceJinanChina

Personalised recommendations